› 5e2w

X-ray diffraction
1.5Å resolution

Anti-TAU AT8 FAB with triply phosphorylated TAU peptide

Released:
DOI: 10.2210/pdb5e2w/pdb
PDB entry 5e2w coloured by chain, front view.
PDB entry 5e2w coloured by chain, side view.
PDB entry 5e2w coloured by chain, top view.
Source organisms:
Primary publication:
Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8.
Malia TJ, Teplyakov A, Ernst R, Wu SJ, Lacy ER, Liu X, Vandermeeren M, Mercken M, Luo J, Sweet RW, Gilliland GL
Proteins 84 427-34 (2016)
PMID: 26800003

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
  • not assigned
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
hetero trimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-229884 (preferred)
Entry contents:
3 distinct polypeptide molecules
Macromolecules (3 distinct):
AT8 LIGHT CHAIN Chain: L
Molecule details ›
Chain: L
Length: 219 amino acids
Theoretical weight: 24.03 KDa
Source organism: Mus musculus
Expression system: Homo sapiens
Structure domains: Immunoglobulins
AT8 HEAVY CHAIN Chain: H
Molecule details ›
Chain: H
Length: 222 amino acids
Theoretical weight: 24.1 KDa
Source organism: Mus musculus
Expression system: Homo sapiens
Structure domains: Immunoglobulins
Microtubule-associated protein tau Chain: P
Molecule details ›
Chain: P
Length: 18 amino acids
Theoretical weight: 2.04 KDa
Source organism: Homo sapiens
Expression system: Not provided
UniProt:
  • Canonical: P10636 (Residues: 511-528; Coverage: 2%)
Gene names: MAPT, MAPTL, MTBT1, TAU

Ligands and Environments

No bound ligands
2 modified residues:
Ligand SEP 2 x SEP
Ligand TPO 1 x TPO

Experiments and Validation Details

Entry percentile scores
X-ray source: CLSI BEAMLINE 08ID-1
Spacegroup: C2
Unit cell:
a: 115.62Å b: 61.02Å c: 84.12Å
α: 90° β: 133.11° γ: 90°
R-values:
R R work R free
0.216 0.216 0.22
Expression systems:
  • Homo sapiens
  • Not provided

Quick links

Citations

13 review citations

Tau and tauopathies.
Arendt et al. (2016)
12 more

7 mentions without citation

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.
Plotkin et al. (2020)
6 more